PT  - JOURNAL ARTICLE
AU  - SHIN, HYERAN
AU  - KIM, YONGHYO
AU  - LEE, YEHYEONG
AU  - KIM, JISOO
AU  - RYU, YEONG CHAN
AU  - KANG, DONG-WOO
AU  - KIM, TAE IL
AU  - CHO, YONG-HEE
TI  - Chlorhexidine Dihydrochloride Shows Anti-tumor Effects in Desmoid Tumors and Colorectal Cancer
AID  - 10.21873/anticanres.17369
DP  - 2024 Dec 01
TA  - Anticancer Research
PG  - 5435--5443
VI  - 44
IP  - 12
4099  - http://ar.iiarjournals.org/content/44/12/5435.short
4100  - http://ar.iiarjournals.org/content/44/12/5435.full
SO  - Anticancer Res2024 Dec 01; 44
AB  - Background/Aim: Desmoid tumors (DTs), or aggressive fibromatosis, are rare neoplasms arising from connective tissue, frequently exhibiting local invasiveness. The limited treatment options and high recurrence rates of DTs highlight the need for novel therapeutic strategies. This study investigated the efficacy of chlorhexidine dihydrochloride (CD) in inhibiting the growth of DTs and colorectal cancer (CRC). Materials and Methods: A mouse model with Apc mutations, specifically Apc1638N/+, was generated to study DTs. DT cells (Apc1638N+) (DTA) were collected from the mice for in vitro experiments. DTA were treated with CD, along with a CRC cell line (HCT-116), and tumor organoids derived from Apc1638N/+ mice. The effects of CD were assessed through cell viability assay (WST assay), colony formation assay, and cell migration assay. We tested the induction of cell apoptosis through caspase 3/7 activity assays and immunoblot analysis of cleaved-caspase 3 and cleaved-PARP1. Additionally, CD was tested for its anti-tumor efficacy using an in vivo CRC xenograft model with the HCT-116 cell line. Results: CD significantly inhibited the viability, migration, and colony formation of DTA and CRC cells. It remarkably decreased the tumor growth in organoids derived from intestinal tumor cells in the Apc1638N/+ mouse model. Furthermore, CD showed anti-tumor effects in an in vivo CRC xenograft model using the HCT-116 cell line. Conclusion: CD represents a promising therapeutic strategy for treating both DTs and CRC.